Introduction
Bile acids (BAs) are cholesterol derivatives synthesized in the liver. After their conjugation to glycine and taurine, they are secreted into the bile duct and transported into the gall bladder, from where they are released into the duodenum. They are amphipathic molecules that assume various functions, such as emulsifying lipids and vitamins to enable their resorption in the intestine, but they also act as signaling molecules, as they bind to the nuclear hormone receptors and, therefore, can activate genes that play major roles in BA synthesis, BA transport, or lipid metabolism (1) . During the digestion process, about 90% of the BAs are reabsorbed from the intestine, partly as primary BA and partly after conversion by intestinal microbiota into secondary BA. Finally, the uptake of BA from the portal vein into the hepatocytes closes the loop of the so-called enterohepatic circulation to ensure BA preservation. This uptake is highly efficient and leads to a BA concentration downstream of the liver that is 5-6 times lower (2-3 µmol/L) as compared to the portal vein (14 µmol/L).
with high-flux dialysis as well as different adsorbents and the evaluation of their binding to plasma proteins.
Methods

Plasma and plasma fractions
Human serum albumin solution (200 g/L) was purchased from Baxter. Fractionated plasma was generated from fresh frozen plasma (Red Cross, Linz, Austria) by filtration through an Albuflow filter (Fresenius Medical Care).
Bile acids
Lithocholic acid (LCA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), cholic acid (CA), glycocholic acid (GCA) and taurocholic acid (TCA) were purchased from Sigma Aldrich. Plasma was spiked by dissolving the BAs in 0.3 M NaOH and adding this solution to plasma. After 1 hour of mixing at 37°C, the spiked plasma was neutralized with the same amount of 0.3 M HCl. The plasma concentration of each BA was 100 µmol/L.
Binding to plasma compounds
In order to identify the non-protein-bound fraction of the different BAs, the spiked medium (plasma, fractionated plasma, and human serum albumin [HSA]) was centrifuged in spin columns with a molecular weight cut-off of 10 kDa ( Corning Spin-X UF concentrator) for 20 minutes at 15,000 g. The free fraction of each BA was calculated from the concentration of the BAs in the spiked plasma and in the filtrate of the spiked plasma.
Adsorption
The characterization of the adsorbents was carried out in batch experiments with 10% v/v adsorbent (9 mL spiked and citrated plasma, 1 mL adsorbent) with gentle shaking at 37°C. Amberchrom CG161c as well as the clinically approved products Cytosorb, diaMARS AC250, Hemosorba, prometh 01 and prometh 02 were used (Tab. I). Samples were taken at 5, 15, 30, 60 and 120 minutes and stored at -20°C until analysis.
Dialysis, clearance and sieving coefficient
Dialysis experiments were carried out using stand-alone pumps (Ismatec MCP Process with Pro 380AD pump head) in miniaturized in vitro setups at 37°C using pediatric high-flux filters (FX paed; Fresenius Medical Care) and 500 mL citrated plasma (Red Cross, Linz, Austria). To avoid uncontrolled filtration, fluid balance was controlled using 2 pumps in the dialysate circuit, 1 upstream and another 1 downstream of the dialyzer. The flow rates were Q P = 50 mL/min and Q D = 2000 mL/h for the plasma and the dialysate flow, respectively. Samples were taken upstream (c in ) and downstream (c out ) of the dialyzer over 180 minutes (n = 8). The clearance (C) in mL/ min was calculated using the formula C = Q P ·(c in -c out )/c in , the extraction rate (R) in % of plasma flow was calculated using the formula R = 100·(c in -c out )/c in . From the clearance data for each BA, the trend of BA decrease over time for a patient with 3360 mL plasma was calculated using the formula C = V/t · Ln(c o /c t ), where V = plasma volume (mL), t = treatment time (min), c o = BA concentration at the beginning of the treatment (µM), c t = BA concentration at time t (min).
For the most hydrophilic and the most hydrophobic BA used in this study, the sieving coefficients were determined using pediatric Albuflow filters as well as pediatric high-flux dialyzers (Albuflow paed and FX paed; Fresenius Medical Care). The experiments were conducted in citrated plasma at plasma and filtrate flow rates of 50 and 5 mL/min, respectively. Samples were taken after 10, 30 and 60 minutes, and the sieving coefficient (SC) in percent was calculated using the formula SC = (2·c f / (c i + c o ))·100, where c f , c i and c o are the BA concentration in the filtrate, upstream and downstream of the dialyzer, respectively.
Analysis
BA were analyzed using a colorimetric test kit (Trinity Biotech) with a Roche/Hitachi 902 auto-analyzer. Since this test kit does not differentiate between the individual BA, only 1 BA was spiked into each batch in order to distinguish the adsorbent characteristics for each BA.
Statistics
Means and standard deviations were calculated using Microsoft Excel 2010. In order to compare the 2 filters regarding SC, data (n = 12) were checked for normal distribution before Mann-Whitney rank sum test for significance was conducted using SigmaPlot 13.0 for Windows (Systat Software).
Results
Binding of BA to plasma compounds
Only a small fraction of BA is present in free form and not bound to plasma compounds (Fig. 1) . Compared to plasma, lower ratios of BA are protein bound in HSA solution, which indicates that in plasma, BAs are not only bound to albumin, but also to other proteins or lipoproteins. In fractionated plasma, which contains practically no lipids but mainly albumin and other proteins or lipoproteins in the size range of albumin or below, the ratio of bound BA was between the ratio found for HSA and plasma. Figure 2 shows the results of the adsorption batch tests. The anion exchanger prometh 02 removed the different BA according to their hydrophilicity. Within 2 hours, the most hydrophobic and the most hydrophilic BA, namely LCA and TCA, were adsorbed by 24% and 61%, respectively. The removal of BA by neutral adsorbents followed the same pattern: the more hydrophilic the BA, the more effective was the adsorption. However, there were differences between the adsorbents. Hemosorba, Cytosorb, prometh 01, and diaMARS AC250 removed the 3 more hydrophilic BA more effectively than the hydrophobic ones. Amberchrom CG161, a strongly hydrophobic adsorbent, was capable of effectively removing the hydrophobic BA, as well. Figure 3 shows the removal for BA by high-flux dialysis. The removal correlates with the hydrophilicity of the BA and confirms the findings of the binding study (Fig. 1) . The progressions of the BA concentration for TCA, GCA, CA and DCA over time were calculated for a virtual treatment of a patient with a plasma volume of 3,360 mL and are shown in the insert of Figure 3 . While TCA and GCA are removed by about 50% during 24 hours of treatment, CA and DCA can only be removed by 35% and 7%, respectively. However, it should be taken into account that this model ignores the rebound of BA during the treatment and that the decrease would be significantly lower under clinical conditions.
Depletion of BA by adsorption
Depletion of BA by dialysis
Sieving coefficient of BA
The sieving coefficient (SC) for TCA was 48.3% ± 1.7% and 8.2% ± 1.5% for the Albuflow and the FX paed filter, respectively, and 50.2% ± 12.1% and 0.8% ± 0.7% for LCA (n = 12). The SC for both BAs was significantly higher with the Albuflow filter than with the FX filter (p<0.001). Since the Albuflow filter offers a high SC for albumin, the albumin-bound as well as the free fraction of BA can pass the filter. Therefore, there is no significant difference between the SC of the 2 BAs for the Albuflow filter (p = 0.436). However, due to the fact that a highflux dialyzer has much smaller pores, only the free fraction of BA can pass the high-flux filter, and the SC is significantly higher for TCA than for the strongly albumin-bound LCA (p = 0.001).
Discussion
Our data show that BAs in plasma are not only bound to albumin, but also to other proteins and lipoproteins, confirming the findings by other authors (4, 21) .
Our results indicate that adsorptive removal of BA is possible with anion exchangers as well as with neutral resins. This may be explained by the fact that BA are amphiphilic molecules offering 2 different moieties for adsorption. The hydrophobicity of BA increases with decreasing number of hydroxyl groups. Although TCA, GCA and CA have the same amount of hydroxyl groups, TCA and GCA are more hydrophilic, since they are conjugated to taurine and glycine, respectively. This is manifested in the lower pKa of TCA and GCA (Tab. II).
While hydrophilic BA can be removed by anion exchangers as well as by moderately hydrophobic neutral adsorbents, hydrophobic BA can only be removed at high efficiency by strongly hydrophobic neutral resins since these BA such as LCA, CDA and DCA are strongly albumin bound. This was shown in this study for the Amberchrom CG161c, which has, in addition to its hydrophobicity, a pore size that is optimal for the depletion of albumin-bound metabolites (22) . The other adsorbents tested showed limited removal rates for strongly hydrophobic BA.
The pKa (23, 24) and the number of hydroxyl groups correlate with the hydrophilicity and the removability of bile acid with commercially available extracorporeal blood purification systems.
Although anion exchangers are applied in extracorporeal blood purification devices to remove bilirubin, hydrophilic BA and other anionic compounds, it should be noted that anionic anticoagulants such as heparin and citrate are removed by these adsorbents. Therefore, strongly hydrophobic resins might be a better choice for the removal of amphiphilic substances.
Our results show that the removability of BA, both by dialysis as well as by adsorption, decreases with their hydrophobicity and, therefore, with the affinity of BA to albumin or to other proteins and lipoproteins in plasma. These findings match the hepatic reabsorption of the different BA by the healthy liver at the end of the enterohepatic cycle (25) . The poor removal of strongly hydrophobic BA by dialysis suggests that for an efficient removal of these BAs, especially under clinical conditions where patients produce BA during treatment, hydrophobic adsorbents should be used. Studies by many authors compare different technologies such as adsorption, albumin dialysis, or conventional dialysis, or even compare dialyzer materials regarding the removability of BA. Here, we show that the removability of BAs strongly depends on their hydrophobicity. While mainly the conjugated BA, which can be removed more easily from blood, show increased levels in patients with hepatobiliary diseases, hydrophobic BAs are especially cytotoxic due to their ability to destabilize cell membranes and can trigger apoptosis or induce necrosis (16, 26) . They should, therefore, be considered important targets for removal. For these BAs, the hydrophobic adsorbent CG161c offers promising adsorption characteristics for all tested BAs. Our results suggest that among the available membrane/adsorption based systems, the Prometheus system is superior by combining the highly permeable Albuflow filter with efficient adsorbents. Cytosorb as well as Hemosorba are whole blood adsorbents without the need for prior plasma separation and are, therefore, particularly promising for the removal of albumin-bound BA.
It should be noted that membrane/adsorption-based systems are mainly based on polysulphone membranes, and there has been controversial discussion about these membranes regarding their impact on the development of pruritus. While some authors showed that hemodialysis patients treated with polysulphone membranes suffered more commonly from pruritus than patients treated with hemophane or cuprophane membranes (27) , others found that hemophane and cellulose membranes promote pruritus more than polysulfone (28, 29) , or that high-flux polyacrylonitrile and polymethylmethacrylate membranes can reduce pruritus, the latter due to their ability to remove larger uremic toxins and ions by a combination of convection and adsorption (20, 30) . Therefore, further observations are needed to determine the preferred membrane material for the treatment of patients suffering from pruritus.
Since various diseases, including conditions without apparent liver disease (31) , may be associated with pruritus based on significantly altered BA patterns, this may influence the choice of adequate adsorbents. However, compared to dialysis, the application of adsorption technology in clinical practice is expensive and complex. Since the pathogenesis and the pathophysiology of bile acid patterns which are responsible for pruritus are not yet completely understood, it cannot be guaranteed that adsorption technology will improve the patients' condition.
